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Bicycle ring closure on a mixture of (4aS,8aR)- and (4aR,8aS)-ethyl 2-oxodecahydro-1,6-
naphthyridine-6-carboxylate, followed by conversion of the separated cis and trans isomers to the 
corresponding thioamide derivatives, gave (4aSR,8aRS)-ethyl 2-sulfanylidenedecahydro-1,6-
naphthyridine-6-carboxylate, C11H18N2O2S. Structural analysis of this thioamide revealed a structure 
with two crystallographically independent conformers per asymmetric unit (Z′ = 2). The reciprocal 
bicycle ring closure on (3aRS,7aRS)-ethyl 2-oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxyl-
ate, C10H16N2O3, was also accomplished in good overall yield. Here the five-membered ring is 
disordered over two positions, so that both enantiomers are represented in the asymmetric 
unit. The compounds act as key intermediates towards the synthesis of potential new polycyclic 
medicinal chemical structures. 
Keywords: X-ray crystal structure; privileged structure; bicycle formation; biologically 
active compounds; NMR evaluation; medicinal chemistry; GPCRs; polycyclic scaffolds. 
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1. Introduction 
The bicyclic lactams (1-1), (1-2), (2-1) and (2-2) (see Scheme 1 ) represent both interesting 
chemical scaffolds and important synthetic precursors to novel polycyclic scaffolds for application 
in medicinal chemistry drug discovery programmes. 
The resulting polycyclic compounds derived from these bicyclic scaffolds could be used in the 
design of molecules to modulate various biological targets and therefore represent a new class of 
privileged structures (Welsch et al., 2010 ; DeSimone et al., 2004 ) for targeting, for 
example, G protein-coupled receptors (GPCRs). GPCRs are 7-transmembrane receptors whose 
function is to regulate multiple disease states and represent one of the major target families for 
currently prescribed drugs in the clinic (Filmore, 2004 ). Continued efforts to discover new 
compounds that modulate these important biological targets therefore remain of great importance 
to the biopharmaceutical industry. 
 
The chemical scaffolds (1-1), (1-2), (2-1) and (2-2) themselves appear underrepresented in the 
medicinal chemical literature and therefore warrant further investigation. It had been reported that 
compound (3) (Scheme 2 ) targets the bradykinin receptor (Hu et al., 2005 ), which is a 
member of the GPCR family and has a key role as a pro-inflammatory mediator (Hall, 1997 ; 
Yogi et al., 2009 ). Compounds (4a) and (4b) (Scheme 2 ) act as serotonin 5HT receptor 
ligands (Fevig et al., 2006 ). The serotonin receptors are found in the central and peripheral 
nervous system and mediate both excitatory and inhibitory neurotransmission (Wang et al., 2013
; Wacker et al., 2013 ; Raote et al., 2007 ). 
We were interested in the synthesis of the core bicyclic molecular scaffolds [e.g. compounds of 
type (5) (see Scheme 2 ), where X = O] contained within these biologically active compounds, 
which therefore necessitated the synthesis, separation and full characterization of the 
resulting diastereoisomers obtained from our synthetic sequence. So far no robust synthetic 
procedure has been reported for the interesting bicyclic 6,6-lactam scaffolds (1-1) and (1-2) (see 
Scheme 1 ). However, the 6,5-system, e.g. compounds (2-1) and (2-2) (see Scheme 1 ), was 
recently reported in the literature (Martini et al., 2011 ). Unfortunately, in our hands, we were 
unable to repeat the published synthetic procedure and so we needed to further investigate both 
the synthesis and structural assignment of these key bicyclic intermediates. Upon completion of 
our robust and high-yielding synthetic sequence to both the 6,5- and 6,6-bicyclic ring systems, we 
were unable to assign the relative stereochemistries of the separated cis and trans isomers by 
NMR spectroscopic analysis due to the complexity of the overlapping proton signals and therefore 
we required final structural confirmation through X-ray crystallographic analysis. 
 
2. Experimental 
We embarked on a racemic synthesis of compounds (1) [isomers (1-1) and (1-2)] and (2) 
[isomers (2-1) and (2-2)] (see Scheme 1 ). In our synthetic strategy, no enantioselective 
conditions were used to synthesize the bicyclic ring systems. As a consequence, each of the 
resulting separated diastereoisomers exists as a pair of enantiomers, which are for simplicity 
drawn as one single stereoisomer. Our initial attempts to obtain crystals of sufficient quality for X-
ray crystallographic analysis from the separated amide compounds (1-1) or (1-2) were 
unprofitable. However, from isomer (1-1), it was subsequently discovered that the corresponding 
thiolactam (8-1) (see Scheme 3 ) was highly crystalline and delivered crystals of sufficient 
quality for X-ray crystallographic structure determination. 
2.1. Synthesis and crystallization of thiolactam (8-1) (see Scheme 3 ) 
The synthesis started from the known ethyl ester ethyl 3-(3-ethoxy-3-oxopropyl)-4-oxopiperidine-
1-carboxylate, (6) (Borne et al., 1984 ), which was converted into the methoxime derivative 
ethyl 3-(3-ethoxy-3-oxopropyl)-4-(methoxyimino)piperidine-1-carboxylate, (7), using O-methyl-
hydroxylamine hydrochloride in pyridine to yield a 1:1.5 mixture of diastereomers (see Scheme 3
). Subsequent conversion to the bicyclic lactams ethyl (4aSR,8aRS)-2-oxodecahydro-1,6-
naphthyridine-6-carboxylate, (1-1), and ethyl (4aSR,8aSR)-2-oxodecahydro-1,6-naphthyridine-6-
carboxylate, (1-2), was accomplished with Raney nickel in methanolic 7 N NH3 under an 
atmosphere of hydrogen. Final thioamide formation on the separated lactam diastereoisomer (1-1) 
was achieved using Lawesson's reagent [i.e. 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithia-
diphosphetane 2,4-disulfide; Occhiato et al., 2004 ], giving the thiolactams (4aSR,8aRS)-ethyl 
2-sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate, (8-1), and ent-(8-1) (see Scheme 3
). 
 
2.1.1. Ethyl 3-(3-ethoxy-3-oxopropyl)-4-(methoxyimino)piperidine-1-carboxylate, (7) 
To a solution of ketone (6) (3.0 g, 11.0 mmol, 1.0 equivalent) in pyridine (21 ml) was added O-
methylhydroxylamine hydrochloride (1.11 g, 13.3 mmol, 1.2 equivalents) and the reaction was 
stirred at room temperature under a nitrogen atmosphere overnight. The reaction mixture was 
evaporated and diluted with diethyl ether (150 ml) and water (150 ml). The organic phase was 
washed with hydrochloric acid (1 M, 60 ml) and brine (150 ml). The combined organic phases were 
dried over MgSO4, filtered and the solvent was evaporated under reduced pressure to yield ethyl 3-
(3-ethoxy-3-oxopropyl)-4-(methoxyimino)piperidine-1-carboxylate, (7a)/(7b), as a yellow/orange 
oil (yield 2.80 g, 84%; 1:1.5 diastereomeric mixture). 
RF (petroleum ether/ethyl acetate, 2:1 v/v) = 0.56; 1H NMR (400 MHz, CDCl3): δ 4.16–4.08 
(4H, m), 3.85 (2H, s), 3.81 (1H, s), 3.61 (1H, m), 3.39 (1H, m), 3.23 (1H, m), 2.92–2.67 
(2H, m), 2.43–2.21 (4H, m), 1.95 (1H, m), 1.82–1.72 (1H, m), 1.26, 1.25 (6H, 2t, J = 7.47 
Hz); 13C NMR (100 MHz, CDCl3): δ 173.2, 173.0, 157.1, 155.7, 61.7, 61.5, 61.3, 60.5, 48.4, 44.3, 
42.7, 40.6, 31.9, 24.9, 24.8, 14.7, 14.3; HRMS m/z (C14H24N2O5): calculated 301.1758 [M+ H]+, 
found 301.1699. 
2.1.2. Ethyl 2-oxodecahydro-1,6-naphthyridine-6-carboxylate, (1-1 and 1-2) 
To a stirred solution of (7a)/(7b) (200 mg, 0.66 mmol, 1 equivalent) in methanolic NH3 (7 N, 5 ml) 
was added Raney nickel (50 mg, 50% slurry in water) and the resulting mixture was stirred under 
a hydrogen atmosphere overnight. The reaction mixture was filtered through Celite and the filter 
cake was washed with methanol (3 × 10 ml). The solvent was evaporated under reduced pressure 
and the crude product was purified by flash chromatography (ethyl acetate/petroleum 
ether/methanol 9:1:2 v/v/v) to yield two isomers of ethyl 2-oxodecahydro-1,6-naphthyridine-6-
carboxylate, viz. (1-1) (yield 40 mg, 26%; colourless oil) and (1-2) (yield 90 mg, 60%; colourless 
oil) (combined yield 130 mg, 86%). 
Isomer 1, viz. (1-2): RF (petroleum ether/ethyl acetate, 10:1 v/v + 15% MeOH) = 0.36; 1H NMR 
(400 MHz, CDCl3): δ 6.20 (1H, bs), 4.24, (2H, bm), 4.12 (2H, q, J = 7.6, 14.8 Hz), 3.06 
(1H, dddd, J = 4.0, 9.8, 12.3 Hz), 2.81–2.74 (1H, m), 2.52–2.34 (3H, m), 1.83–1.76 (2H, m), 
1.55–1.41 (3H, m), 1.24 (3H, t, J = 7.4 Hz); 13C NMR (100 MHz, CDCl3): δ 172.2, 155.4, 61.7, 
56.4, 47.3, 42.3, 38.9, 32.2, 30.9, 24.5, 14.7. HMRS m/z (C14H19N2O3): calculated 227.1390 [M + 
H]+, found 227.1265. 
Isomer 2, viz. (1-1): RF (petroleum ether/ethyl acetate, 10:1 v/v + 15% MeOH) = 0.30; 1H NMR 
(400 MHz, CDCl3): δ 7.33 (1H, bs), 4.11–4.04 (2H, m), 3.57–3.51 (3H, m), 3.40–3.36 (1H, m), 
3.26–3.20 (1H, m), 3.15 (2H, t, J = 6.9 Hz), 2.03–1.98 (1H, m), 1.86–1.62 (4H, m), 1.20 
(3H, t, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3): δ 172.6, 155.6, 61.7, 50.6, 44.7, 40.5, 32.7, 30.5, 
28.9, 22.0, 14.9; HRMS m/z (C14H19N2O3): calculated 227.1390 [M + H]+, found 227.1229. 
2.1.3. Ethyl 2-sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate, (8-1) and ent-(8-1) 
To a solution of (1-1) (80 mg, 0.35 mmol, 1 equivalent) in toluene (1 ml) was added Lawesson's 
reagent (71 mg, 0.17 mmol, 0.5 equivalents) and the mixture was refluxed for 20 min. The 
reaction mixture was evaporated under reduced pressure and purified by 
flash chromatography (ethyl acetate/petrol ether/methanol, 10:1:0.5 v/v/v) to yield ethyl 2-
sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate [(8-1) and ent-(8-1)] as a colourless 
waxy oil (yield 80 mg, 94%). The resulting oil was dissolved in a mixture of ethyl acetate and 
diethyl ether and the solvent was allowed to evaporate slowly. After evaporation of half of the 
solvent, diisopropyl ether was added and the solvent was allowed to evaporate slowly to afford 
clear colourless crystals, which were used for X-ray structural determination that allowed us an 
unambiguous assignment of the regiochemistry of the separated isomers (Fig. 1 ). 
  
 
Figure 1  
The molecular structures of the two rotamers of (4aSR,8aRS)-(8-1). 
Displacement ellipsoids are drawn at the 50% probability level. 
RF (petroleum ether/ethyl acetate, 10:1 v/v) = 0.45; 1H NMR (400 MHz, CDCl3): δ 8.34 (1H, bs), 
4.12 (2H, dq, J = 2.3, 7.2, 14.4 Hz), 3.64–3.52 (3H, m), 3.46–3.42 (1H, m), 3.33–3.27 (1H, m), 
2.93 (2H, qt, J = 7.1, 19.6, 40.4 Hz), 2.10–2.06 (1H, m), 1.88–1.72 (4H, m), 1.25 (3H, t, J = 7.0 
Hz); 13C NMR (100 MHz, CDCl3): δ 202.1, 155.7, 61.7, 53.1, 44.9, 40.6, 37.7, 31.7, 29.3, 21.4, 
14.9; m.p. 401–403 K; HRMS m/z (C11H19H2O2S): calculated 243.1162 [M+ H]+, found 243.1003. 
2.2. Synthesis and crystallization of bicyclic lactam (2-1) (see Scheme 4 ) 
Commercial ethyl 4-oxopiperidine-1-carboxylate, (9), was converted into the tert-butyl ester ethyl 
3-(2-tert-butoxy-2-oxyethyl)-4-oxopiperidine-1-carboxylate, (10), using LDA and tert-butyl 
bromoacetate. The tert-butyl ester (10) was converted to the substituted benzylamine ethyl 4-
benzylamino-3-(2-tert-butoxy-2-oxoethyl)piperidine-1-carboxylate, (11), via a reductive amination 
reaction using benzylamine and sodium triacetoxyborohydride in dichloroethane. Compound (11) 
was transesterified with 0.6 M HCl in methanol to yield the ester ethyl 4-benzylamino-3-(2-meth-
oxy-2-oxoethyl)piperidine-1-carboxylate, (12), which was catalytically deprotected (Pd/C in MeOH 
under an atmosphere of hydrogen). The final ring closure to the key bicyclic lactams ethyl 2-oxo-
octahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylate, viz. (2-1) and (2-2), was carried out with 
potassium carbonate in methanol (see Scheme 4 ). Unlike the 6,6-membered-ring compound 
(1), the 6,5-membered-ring compound (2) did not need further elaboration to the thioamide to 
obtain high-quality crystals. 
 2.2.1. Ethyl 3-(2-tert-butoxy-2-oxyethyl)-4-oxopiperidine-1-carboxylate, (10) 
To a solution of diisopropylamine (5.6 g, 7.8 ml, 55.6 mmol, 1.9 equivalents) in tetrahydrofuran 
(THF; 175 ml) at 273 K was added n-BuLi (18.5 ml, 2.5 M in hexane, 46.2 mmol, 1.6 equivalents) 
and the mixture was stirred for 30 min. The mixture was cooled to 195 K and ethyl 4-oxo-
piperidine-1-carboxylate, (16) (5.0 g, 4.4 ml, 29.2 mmol, 1 equivalent), was added and the 
mixture was stirred for an additional 30 min at 195 K. A solution of tert-butyl bromoacetate (9.2 g, 
7.0 ml, 47.2 mmol, 1.62 equivalents) in THF (17.5 ml) and hexamethylphosphoramide (HMPT; 2.9 
ml) was added and the yellow reaction mixture was warmed gradually to room temperature 
overnight. The mixture was quenched with saturated aqueous NH4Cl (200 ml), the phases were 
separated and the aqueous phase was extracted with ethyl acetate (3 × 200 ml). The combined 
organic layers were dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The crude product was purified by flash chromatography (petroleum ether/ethyl acetate, 
3:1 v/v) to yield tert-butyl ester (10) in 50% yield. 
RF (petroleum ether/ethyl acetate, 3:1 v/v) = 0.28; 1H NMR (400 MHz, CDCl3): δ 4.34 (2H, bs), 
4.13 (2H, q, J = 7.0, 14.5 Hz), 3.21 (1H, m), 2.94–2.80 (2H, m), 2.64–2.50 (2H, m), 2.39 (0.68 
H, t, J = 3.9 Hz), 2.35 (0.32 H, t, J = 4.3 Hz), 2.25–2.18 (1H, m), 1.45 (9H, s), 1.28 (3H, t, J = 
7.1 Hz); 13C NMR (100 MHz, CDCl3): δ 207.2, 170.6, 155.2, 80.9, 61.9, 47.9, 46.5, 43.6, 40.7, 
32.7, 28.0, 14.6. 
2.2.2. Ethyl 4-benzylamino-3-(2-tert-butoxy-2-oxoethyl)piperidine-1-carboxylate, (11) 
To a solution of tert-butyl ester (10) (1.43 g, 5.01 mmol, 1 equivalent) in dichloroethane (22 ml) 
was added benzylamine (0.65 ml, 0.63 g, 5.90 mmol, 1.17 equivalents) and sodium triacetoxy-
borohydride (1.80 g, 8.53 mmol, 1.70 equivalents). The resulting mixture was stirred overnight 
under an atmosphere of dry nitrogen. The reaction mixture was quenched with saturated aqueous 
NaHCO3 (150 ml) and the aqueous phase was extracted with ethyl acetate (3 × 150 ml). The 
combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash chromatography (petroleum ether/ethyl 
acetate, 1:5 v/v) to yield (10) as a clear colourless oil (yield 1.77g, 94%). 
RF (ethyl acetate/petroleum ether 6:1 v/v) = 0.45; 1H NMR (400 MHz, CDCl3): δ 7.34–7.31, 7.29–
7.23 (5H, m), 4.12 (2H, q, J = 7.1, 14.3 Hz), 4.04–3.69 (4H, m), 3.11–2.89 (1H, m), 2.86–2.81 
(1H, m), 2.74–2.46 (1H, m), 2.37–2.30 (1H, m), 2.18–2.12 (1H, m), 1.91–1.76 (1H, m), 1.56–
1.46 (1H, m), 1.45 (9H, s), 1.24 (3H, t, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3): δ 172.5, 155.8, 
155.4, 140.6, 140.4, 128.4, 128.3 (2), 128.1 (2), 126.9 (2), 82.6, 80.4, 80.3, 62.2, 61.5, 61.2, 
59.2, 50.9, 50.4, 45.9, 42.5, 42.4, 28.2, 14.7 (2); HRMS m/z (C22H33N2O4): calculated 377.2435 
[M + H]+, found 377.2422. 
2.2.3. Ethyl 2-oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylate, (2-1) and (2-2) 
To a solution of (11) (1.70 g, 4.52 mmol, 1.0 equivalents) in MeOH (50 ml) was added hydrochloric 
acid (0.6 M, 4 ml) and the reaction mixture was stirred for 4 d. A further aliquot of hydrochloric 
acid (concentrated, 1 ml) was added and the mixture was stirred for a further 2 d. The reaction 
mixture was evaporated under reduced pressure and subsequently diluted with MeOH (30 ml) and 
dilute hydrochloric acid (0.5 M, 2 ml). The reaction was stirred for 48 h at room temperature. After 
evaporation, the crude product was obtained as the hydrochloride salt and was used without 
further purification. To a solution of the hydrochloride salt (550 mg, 1.49 mmol, 1 equivalent) in 
MeOH (15 ml) was added Pd/C (10% w/w, 100 mg) and the reaction mixture was stirred at room 
temperature overnight under an atmosphere of hydrogen. The reaction mixture was filtered 
through Celite, the filter cake was washed with MeOH (3 × 10 ml) and the filtrate was evaporated 
to give (11) which was used without further purification. To a solution of the crude product 1-eth-
oxycarbonyl-3-(2-methoxy-2-oxoethyl)piperidin-4-aminium chloride in MeOH (6 ml) was added 
anhydrous K2CO3 (200 mg) and the reaction mixture was stirred overnight at room temperature. 
The reaction mixture was quenched with water (30 ml) and the aqueous phase was extracted with 
ethyl acetate (3 × 30 ml). The combined organic layers were dried over MgSO4, filtered and the 
solvent was evaporated under reduced pressure. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether/methanol, 10:1:1 v/v/v) to yield ethyl 2-
oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylate which was separated by flash column 
chromatography to afford two isomers, viz. (2-1) (yield 168 mg, 16%) and (2-2) (yield 286 mg, 
28%) (combined yield 454 mg, 45%), that slowly crystallized on standing. Crystals suitable for the 
X-ray crystallographic analysis were grown by slow evaporation of an ethyl acetate solution and it 
was found that isomer (2-1) afforded crystals of sufficient quality to allow the unambiguous 
assignment of the regiochemistry (Fig. 2 ). 
  
 
Figure 2  
An overlay of the two rotamers of isomer (2-1) in the asymmetric unit, 
showing the major (solid bonds) and minor (dashed bonds) disorder 
components. Displacement ellipsoids are drawn at the 50% probability 
level. 
Isomer 1, (2-1): RF (ethyl acetate/petroleum ether/methanol, 10:1:1 v/v/v) = 0.27; 1H NMR (400 
MHz, CDCl3): δ 6.29 (1H, bs), 4.34 (2H, bm), 4.12 (2H, q, J = 7.4, 13.3 Hz), 3.19 (1H, dddd, J = 
3.7, 10.2 Hz), 2.84–2.74 (2H, m), 2.32 (1H, dd, J = 6.7, 15.7 Hz), 2.08 (1H, dd, J = 12.9, 15.7 
Hz), 2.01–1.87 (1H, m), 1.54 (1H, dddd, J = 4.4, 12.9, 24.5 Hz), 1.25 (3H, t, J = 7.4 Hz); 13C NMR 
(100 MHz, CDCl3): δ 178.2, 156.2, 61.5, 60.4, 59.5, 46.4, 43.8, 42.5, 34.9, 14.7, m.p. 377–378 K, 
HRMS m/z (C10H17N2O3): calculated 213.1234 [M + H]+, found 213.0807. 
Isomer 2, (2-2): RF (ethyl acetate/petroleum ether/methanol 10:1:1 v/v/v) = 0.20; 1H NMR (400 
MHz, CDCl3): δ 7.22 (1H, bs), 4.05 (2H, q, J = 7.4, 14.4 Hz), 3.80 (1H, q, J = 4.8, 11.5 Hz), 3.60 
(1H, dd, J = 5.1, 13.9 Hz), 3.46–3.41 (1H, m), 3.24 (1H, dddd, J = 3.6, 9.7, 13.4 Hz), 3.15 
(1H, dd, J = 7.1, 13.8 Hz), 2.52 (1H, bs), 2.38 (1H, dd, J = 10.6, 17.9 Hz), 1.97 (1H, dd, J = 4.7, 
16.6 Hz), 1.87–1.78 (1H, m), 1.70–1.62 (1H, m), 1.18 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, 
CDCl3): δ 178.4, 155.5, 61.5, 51.1, 43.6, 39.3, 34.9, 27.6, 21.2, 14.7; HRMS m/z (C10H16KN2O3): 
calculated 251.0793 [M + K]+, found 251.0761. 
2.3. Refinement 
Crystal data, data collection and structure refinement details are summarized in Table 1 . Upon 
initial refinement of the structure of (2-1), it became obvious that the five-membered ring was 
disordered over two possible positions and that both enantiomers were present in the asymmetric 
unit. The reflection data and raw frames were examined and no signs of larger cells 
or twinning could be found. Structure solution was also attempted in the space groups P21 and Pn; 
in both cases, the disorder was still present. The structure was further examined for twinning with 
the PLATON (Spek, 2009 ) routine TWINROTMATR; again, no signs of twinning were found. 
During refinement, the occupancies of the two disorder components were refined competitively, 
converging at a ratio of 0.533 (3):0.467 (3). Although no geometric restraints were applied to the 
C, N and O atoms, it was necessary to restrain the N—H distances of (2-1) to 0.88 (2) Å, and also 
to restrain the C⋯H distances of this amine H atom to be approximately equal. The positions of the 
H atoms bound to atom C6 in (2-1) and to atoms N1A and N1B in (8-1) were refined, but all other 
H atoms of both (2-1) and (8-1) were placed in idealized positions and refined in riding modes, 
with C—H distances of 0.98, 0.99 and 1.00 Å for CH3, CH2 and CH groups, respectively. Uiso(H) 
values were set at 1.5Ueq(C) for CH3groups and at 1.2Ueq(C,N) for all other H atoms. 
Table 1 
Experimental details 
  (2-1) (8-1) 
Crystal data 
Chemical formula C10H16N2O3 C11H18N2O2S 
Mr 212.25 242.33 
Crystal system, space 
group 
Monoclinic, P21/n Orthorhombic, Pna21 
Temperature (K) 120 120 
a, b, c (Å) 8.5204 (6), 6.4089 (4), 
19.5921 (16) 
15.06714 (17), 8.30759 (8), 
19.5481 (2) 
α, β, γ (°) 90, 96.381 (8), 90 90, 90, 90 
V (Å3) 1063.22 (14) 2446.87 (5) 
Z 4 8 
Radiation type Cu Kα Cu Kα 
μ (mm−1) 0.82 2.26 
Crystal size (mm) 0.33 × 0.14 × 0.08 0.15 × 0.12 × 0.05 
  
Data collection 
Diffractometer Agilent Technologies 
GV1000 diffractometer with 
an Atlas detector 
Agilent Technologies GV1000 
diffractometer with an Atlas 
detector 
Absorption correction Gaussian (CrysAlis PRO; 
Agilent, 2013 ) 
Gaussian (CrysAlis PRO; Agilent, 
2013 ) 
Tmin, Tmax 0.906, 1.120 0.769, 0.976 
No. of measured, 
independent and observed 
[I > 2σ(I)] reflections 
6951, 2130, 1748 21836, 5117, 5030 
Rint 0.040 0.026 
(sin θ/λ)max (Å−1) 0.626 0.634 
  
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.048, 0.136, 1.06 0.034, 0.091, 1.07 
No. of reflections 2130 5117 
No. of parameters 177 297 
No. of restraints 5 1 
H-atom treatment H atoms treated by a mixture 
of independent and 
constrained refinement 
H atoms treated by a mixture of 
independent and constrained 
refinement 
Δρmax, Δρmin (e Å−3) 0.22, −0.21 0.61, −0.20 
Absolute structure – Flack x determined using 2311 
quotients [(I+) − (I−)]/[(I+) + (I−)] 
(Parsons & Flack, 2004 ) 
Absolute structure 
parameter 
– 0.067 (6) 
Computer programs: CrysAlis PRO (Agilent, 2013 ), OLEX2.SOLVE (Bourhis et al., 2014
), SHELXL2014 (Sheldrick, 2008 ), SHELXL2013 (Sheldrick, 2008 ) 
and OLEX2 (Dolomanov et al., 2009 ).  
 
3. Results and discussion 
The X-ray crystal structures of the separated isomers of lactam (2-1) and thiolactam (8-1) were 
required to confirm the relative stereochemistries of the two separated cis and trans isomers as 
the 1H NMR spectra could not categorically assign the relative stereochemistries of the synthesized 
and separated bicyclic ring systems. 
In the case of compound (1-1), it was discovered that obtained thiolactam (8-1) proved highly 
crystalline and formed crystals of sufficient quality for X-ray crystallographic analysis. The 
synthesis of thioamide (8-1) was achieved from ethyl 3-(3-ethoxy-3-oxopropyl)-4-oxopiperidine-1-
carboxylate, (6), following a literature procedure (Shah et al., 2005 ), which was converted in a 
three-step synthesis (68% yield) to thiolactam (8-1) (see Scheme 3 ). 
The coupling constant 3JHH for the syn-H atoms should be found in a range of 0–5 Hz and for 
the anti-H atoms in the range of 7–15 Hz (Reich, 2013 ). 
The 1H NMR spectra for the lactams displayed a clear difference for the ring-junction H atoms in 
both isomers (1-1) and (1-2) (Fig. 3 ). However, analysis of the 1H NMR spectrum proved 
inconclusive as the spectrum clearly showed that only one coupling constant for the proton HA of 
the isomer could be fully determined with 3JHH = 9.8 Hz. 
  
 
Figure 3  
1H NMR data for compound (1), showing isomer (1-2) in the upper 
spectrum and isomer (1-1) in the lower spectrum. 
Thiolactam (8) showed two molecules in the asymmetric unit related by a noncrystallographic axis 
of rotation, although they have different conformations of the carbamate chain (Fig. 4 ). The 
overall packing of the crystal appears to be driven by the interaction of the carbamate and the 
lactam groups (Fig. 5  and Table 2 ). 
Table 2 
Hydrogen-bond geometry (Å, °) for (8-1)  
D—H⋯A D—H H⋯A D⋯A D—H⋯A 
N1A—H1A⋯O12Ai 0.87 (4) 2.02 (4) 2.867 (3) 165 (3) 
N1B—H1B⋯O12Bii 0.83 (4) 2.12 (4) 2.891 (3) 155 (3) 
Symmetry codes: (i) ; (ii) .  
 
  
 
Figure 4  
An overlay of the two molecules of isomer (8-1) in the asymmetric unit, 
showing the different conformations of the carbamate chain. 
Displacement ellipsoids are drawn at the 50% probability level. 
  
 
Figure 5  
The packing of isomer (8-1) in the ac plane. The one-dimensional 
hydrogen-bonded chains extend along the a axis. 
The crystal structure showed typical C—S bond lengths of 1.679 (2) and 1.686 (3) Å for the 
molecules with atom labels A and B, respectively (Wiberg & Wang, 2011 ). The piperidine ring 
adopts a chair conformation with the carbamate group in an equatorial position, with C5—N6—C11 
angles of 119.3 (2)/121.5 (2)° and C7—N6—C11 angles of 123.5 (2)/123.8 (2)° for molecules A/B, 
respectively. 
The torsion angles N1—C9—C10—C4 [46.2 (3)/−46.8 (3)°], C8—C9—C10—C4 [−76.4 (2)/76.8 
(3)°] and C8—C9—C10—C5 [49.2 (3)/−48.9 (3)°] are all synclinal, and from the torsion angles 
N1—C9—C10—C5 [171.73 (19)/−172.60 (19)°] and the resulting antiperiplanar conformation it 
can be seen that the H atoms are arranged in a gauche conformation, giving rise to the chair-like 
conformation of the piperidine ring and the synclinal orientation of atoms H9 and H10. 
For isomers (2-1) and (2-2), another synthetic route had to be established as stable tert-butyl 
ester (10) gave no direct conversion to bicyclic lactam (2-1) or (2-2). Ethyl 3-(2-tert-butoxy-2-
oxoethyl)-4-oxopiperidine-1-carboxylate, (9), was synthesized following the literature procedure 
for the BOC-protected compound (Hubschwerlen et al., 2008 ). The starting material was 
converted via a four-step synthesis into the desired isomers of the bicyclic lactam in an overall 
yield of 21%. It was found that diastereomeric lactams (2-1) and (2-2) could be separated easily 
by flash chromatography. 
Once more the 1H NMR spectra for separated lactams (2-1) and (2-2) showed clear differences 
(Fig. 6 ). In this case, the coupling constant for HA was 3JHH = 10.1 Hz, which was the only 
measurable coupling constant due to extensive overlap of the other NMR signals (Fig. 6 ). 
  
 
Figure 6  
1H NMR data for compound (2), showing isomer (2-1) in the upper 
spectrum and isomer (2-2) in the lower spectrum. 
Compound (2-1) was recrystallized slowly from ethyl acetate to afford crystals of sufficient quality 
for structure determination. The compound was found to crystallize in the centrosymmetric space 
group P21/n, with one molecule in the asymmetric unit. 
Interestingly, the five-membered ring is disordered over two possible positions, so both enanti-
omers are represented in the asymmetric unit due to the piperidine ring flip. In this case, the 
overall packing of the crystal appears to be driven by the interactions of both the carbamate and 
the lactam functional groups. The molecules form hydrogen-bonded dimers (Table 3 ), which 
pack in a classic herringbone fashion (Fig. 7 ). The piperidine ring in the crystal has a chair-like 
conformation and the C8—O15/C8A—O15A bond lengths [1.234 (5)/1.237 (4) Å] are in the typical 
range. The N9—C4—C3/N9—C4—C5 bond angles are 112.06 (15)/109.21 (16)° and the C7—C3—
C4/C7A—C5—C4 bond angles are 98.9 (2)/100.46 (18)°. 
Table 3 
Hydrogen-bond geometry (Å, °) for (2-1)  
D—H⋯A D—H H⋯A D⋯A D—H⋯A 
N9—H9A⋯O15i 0.87 (2) 2.03 (2) 2.889 (4) 174 (4) 
N9—H9B⋯O15Ai 0.87 (2) 1.97 (2) 2.841 (3) 176 (3) 
Symmetry code: (i) -x+2, -y, -z+1.  
 
  
 
Figure 7  
The herringbone packing of isomer (2-1) in the bc plane. 
The torsion angles are synclinal for C7—C3—C4—N9/C7A—C5—C4—N9 [−36.2 (2)/34.4 (2)°] and 
C2—C3—C4—C5/C6—C5—C4—C3 [62.8 (2)/−63.0 (2)°]. With the antiperiplanar torsion angles of 
−158.0 (2)/157.79 (19)° for C7—C3—C4—C5/C7A—C5—C4—C3 and −175.51 (15)/173.55 (16)° 
for C2—C3—C4—N9/C6—C5—C4—N9, the antiperiplanar positon of atoms H4 and H3A/H5B, and 
hence the relative stereochemistry of the molecule was determined. 
In conclusion, we have unambiguously determined the stereochemical outcome for the separated 
disatereomers of the molecular scaffolds (8-1)/(8-2) and (2-1)/(2-2) using X-ray crystallography. 
The crystal structure analyses showed clearly the relative configuration of the bicyclic ring 
systems, resulting in a synclinal orientation for the 6,6-bicyclic ring system and an antiperiplanar 
configuration for the 6,5-ring system. The 1H NMR comparison of compounds (2-1)/(2-2) and (8-
1)/(8-2) showed a clear difference in the chemical shifts of the separated diastereoisomers, but 
could not be used to unambiguously to assign the relative configurations of the 
separated cis and transdiastereoisomers. 
Supporting information 
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3D view 
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 (II) 
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